Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CCKBR | P32239 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8932766 | 0.87 | IDO1 (0.60) | IDO1MAPTKMT2AALDH1A1KDM4E | |
| SCHEMBL29764730 | 0.87 | IDO1 (0.60) | IDO1MAPTKMT2AALDH1A1KDM4E | |
| SCHEMBL8687818 | 0.82 | MAPT (0.44) | MAPTALDH1A1KDM4EPPARGLMNA | |
| SCHEMBL1016495 | 0.81 | FFAR1 (0.55) | MAPTKMT2AALDH1A1HPGDCYP3A4 | |
| SCHEMBL13846754 | 0.81 | HTR2C (0.50) | IDO1MAPTALDH1A1SLC6A4GPR84 | |
| SCHEMBL29764785 | 0.81 | AKT1 (0.42) | IDO1MAPTALDH1A1GPR84GSK3B | |
| SCHEMBL98544 | 0.81 | ALDH1A1 (0.49) | MAPTKMT2AALDH1A1KDM4EHPGD | |
| SCHEMBL6511107 | 0.81 | PPARG (0.46) | IDO1MAPTPPARG | |
| SCHEMBL29764718 | 0.79 | MAPT (0.42) | MAPTALDH1A1GSK3BPPARG | |
| SCHEMBL29764673 | 0.79 | GPR84 (0.52) | MAPTKMT2AGPR84GSK3BPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129364-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2023-04-27 | — | — | US | claimed |
| EP-4083037-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | Yonsei University, University-Industry Foundation(UIF). (KR) | 2022-11-02 | — | — | EP | claimed |
| CN-114945569-A | Pyrrolidine derivative, and pharmaceutical composition for preventing or treating beta-amyloid or Tau-protein related diseases comprising same | 延世大学校产学协力团 | 2022-08-26 | — | — | CN | claimed |
| WO-2021133037-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | 연세대학교 산학협력단 | 2021-07-01 | — | — | WO | claimed |
| US-20230129364-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2023-04-27 | — | — | US | disclosed |
| US-20230129364-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2023-04-27 | — | — | US | disclosed |
| US-20230129364-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2023-04-27 | — | — | US | disclosed |
| EP-4083037-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | Yonsei University, University-Industry Foundation(UIF). (KR) | 2022-11-02 | — | — | EP | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| EP-1585541-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-11-14 | — | — | EP | disclosed |
| WO-1996026207-A1 | THIAZOLIDINE AND OXAZOLIDINE INDOLES WITH HYPOCLYCEMIC ACTIVITY | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1996-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129364-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | MAPT, APP, PRNP | IDO1 3016/4885MAPT 1/4885KMT2A 3977/4885 |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | IDO1 3368/4885MAPT 1785/4885KMT2A 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.